Why a blend rather than two vials Combining both compounds in a single documented lot reduces preparation steps and variability between components in a research setting
Gao X, Yang X, Deng C, Chen Y, Bian Y, Zhang X et al (2025) A mitochondria-targeted nanozyme with enhanced antioxidant activity to prevent acute liver injury by remodeling mitochondria respiratory chain
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Manages oxidative stress by protecting skin cells from free radicals
Individuals with Specific Medical Conditions Several conditions require special consideration when evaluating glutathione safety
This approach is appealing, but it has not been proven in large human trials